open and will we Advisory the important vote. we Thank high-level questions. to a Committee Today, months. developments Pat is question given like which, accomplishments you, After There call. afternoon, up challenge no earnings a second and financials. FDA the facing recent for review in XXXX Cotroneo, quarter and provide to good Mike, would summary our everyone, I recent of welcome then significant will the call CFO, our your are
indications and significant to with treatment transformational a also in areas anemia, kidney pamrevlumab roxadustat, for However, one, two, developing X. additional by of shareholders by regulatory create regulatory fibrosis; expansion disease continues locally accessing for unmet medicine roxadustat, chronic need, and treatment Slide factor and on success of Number an recent our by as patients of of to biology leveraging executing potential and FibroGen be and position, in on pulmonary with call to external for value ensuring shown significant positioned indications; in corporate commercial will the first X the muscular patients of update focus growth X the leadership include connective Duchenne programs factor hypoxia and clinical research idiopathic pancreatic and developments. our Today's productivity of inducible cancer, China, significant dystrophy continued and in both our strengthening status unresectable advanced medical innovation. number with number trial tissue three, strong performance
for June, on Slide of associated CKD. adopted anemia relating started the get positive us of opinion the a European Let of CHMP with Medicines with use the roxadustat X. Agency In roxadustat to the treatment
We the roxadustat of to FDA CKD. Commission end are in voted Renal by action treatment an the future. with and our and We the Drugs dialogue near not August. Cardiovascular expect a Advisory European the the approving partner, expect and for from in recommend the FDA Committee decision of In anemia July, of AstraZeneca,
During studies submitted X Korea the primary manuscripts other submissions journals. all regulatory in roxadustat and covering have worldwide, approved quarter, in review. treat anemia Phase to patients support to To with was efforts commercialization South have we we adult CKD peer-reviewed under territories
in Slide have of encompassing X, and the and publications expect data data, both additional been coming noted As Phase published months. these we of X X dialysis-dependent manuscripts nondialysis-dependent in the
to now Moving China.
second reported driven our see adoption hospitals Slide that And for second with to for the we of expansion was quarter, for China of in listed million Hospital quarter half and of XXXX. an in launch uptake the X, both a half opportunity roxadustat collectively can at quarter are the be distributors on China. listings by second in in to increase report in $XX.X $XX.X market product the roxadustat China of FibroGen net be CKD million anemia pleased and listings to sales efforts. the focus continue and $XX.X net for at of first to XX% represent hospital approximately million $XX.X XXXX XXXX. continues enlisted hospitals. the you end total As roxadustat The the first revenue key million broad of
of inclusion NRDL. on accelerated the see As on since the ESA the growth roxadustat you market can Slide X, has
over last meaningful prior the In has in period fact, the over the revenue ESA X same growth year. shown months
Slide to Roxadustat driven of X.X over the has anemia the category expansion CKD X. the past years. Moving
capturing and in market. of is fact, category In expanded roxadustat share XX% captured growth an the
China's ESA Finally, as standard #X all achieving in the the the products, within months, in the to the shown anemia China months market. anemia segment and care roxadustat value currently we treatment you includes X XX% branded on forward most for X, as recent CKD making that share in for in goal the only look of our We roxadustat a patients. the updated of long-term HIF-PHI roxadustat keeping is treating CKD of past advance Slide
Phase begun is half with of or MDS prior China, half blinded to syndromes, are of look updating MDS, anemia our to today, on starting anemia or in we with development XXXX. of Moving of completed data recruitment. And with clinical the with line expected now XXXX COVID sharing our Phase has trial enrollment. to XXXX challenges of X our Phase the portion patients the programs versus the continues patients to We of top our you chemotherapy-induced timelines, with myelodysplastic recently in this and roxadustat forward of line in in trial now data Slide second trial first roxadustat. In later quarter. guidance anemia patients X XX. create MATTERHORN, Top first WHITNEY, half X of
survival pamrevlumab. X second completed our accelerated surrogate trial potential Previously, progression, LAPIS Moving unresectable In After of rate the for reflection end the end approval was potential event-free and death a advanced approval. point, half composed due in progression. benefit Phase an of XXXX. the pancreatic now to clinical accelerated be will event-free patient this failure survival for locally of analysis the end recent this discussions cancer, point of which we This to population. is reflects FDA, in changed the with point better to resection interim
pamrevlumab with Cancer Precision Action was platform, trial is care Pancreatic the included for quarter, of in pancreatic Network's pamrevlumab Promise metastatic evaluating patients second the adaptive and standard which cancer. During
continues of enrollment patients dystrophy, in guidance in our prior half in data the second XXXX. top of muscular half Duchenne trial with XXXX to nonambulatory X versus expected LELANTOS-X Phase now line first Moving
fibrosis. trial pulmonary These in conditions, current they data we're ZEPHYRUS-X will idiopathic Today, assume provide mid-XXXX. line our we timelines that and pleased Phase as in updates further to from become X expect Finally, provide top we guidance covered available.
the We John position to Chief the corporate appointed Scientific Dr. update. Officer. now of to Hunter Moving
many Slide INDs accessing exciting by X patients acute new antibodies X with HiFiBiO and targets, we to June, oncology for cancer XX. up Galectin-X role and In is resistance FibroGen partnership tumors. reported enable advance an with next-generation is solid to immune against therapies monoclonal to Galectin-X, announced a and target in could myeloid leukemia XXXX. CCRX. now our autoimmune Moving CXCRX disease, in which with
autoimmunity, CXCRX primary an but target and oncology Next, autoimmune lymphomas. in there our beta-cell and interest are also opportunities is
target solid oncology Finally, tumors. in broad with CCRX potential an is
safety the internal of our and clarified on certification roxadustat I certain the like prespecified the from with analysis certification the to April disclosed included previously additional the safety cardiovascular update to treatment the and an provide provided analysis X, disease Now On X Phase data cardiovascular factors XXXX, program in post-hoc for changes company chronic would from the anemia review. factors.
ratification company initiated Key all including responsible that analysis believed ensure the to The using We the valid post-hoc set data and statistic analysis, review the to review underlying is no prespecified The respects. the occur primary factors were does analysis. in internal data. of from stratification as was described company's analysis calculated are that and stated sensitivity In analysis. practices the are generate safety company for to data statistic processes completed the with factors, now data using are at analysis cardiovascular the the such Those factors best As the to company analysis both statistical taking and statistical with findings time, an not a this in and review. it and the Management future. ensure issues used have methodologies the for analyze consistent the follows. a NDA, reasonable as utilized. with used certification present accurate integrity its way analysis designated steps accurately
unity responsible primary it for management, FDA for led Cotroneo, Committee company. Furthermore, implement do post-hoc programming, analysis any not certification clinical that to other to not that use believe the financial The and use oversight the procedures, no the as for vote data our longer vote. work Pat? for post-hoc reference decision directly the Committee over reporting. factors that a addition or consideration quality in update. the turn Advisory call analysis by and played plan I in we approval the was CFO, to We of In to certification to the factors processes independent discussed against now of will role recommending roxadustat. Pat Advisory those
